Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Scilex Holding Co's Enterprise Value is $132.89 Mil.
Scilex Holding Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-17.09 Mil. Therefore, Scilex Holding Co's EV-to-OCF for today is -7.78.
The historical rank and industry rank for Scilex Holding Co's EV-to-OCF or its related term are showing as below:
SCLX'
s EV-to-OCF Range Over the Past 10 Years
Min: -65.31 Med: -8.54 Max: 48.63
Current: -7.78
During the past 7 years, the highest EV-to-OCF of Scilex Holding Co was 48.63. The lowest was -65.31. And the median was -8.54.
SCLX's EV-to-OCF is ranked better than 79.44% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 10.44
vs SCLX: -7.78
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Scilex Holding Co (NAS:SCLX) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Scilex Holding Co's PE Ratio (TTM) for today is calculated as:
Scilex Holding Co's share price for today is $5.38.
Scilex Holding Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-49.700.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Scilex Holding Co EV-to-OCF Related Terms
Scilex Holding Co EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Scilex Holding Co's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Scilex Holding Co's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scilex Holding Co EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Scilex Holding Co's EV-to-OCF falls into.
Scilex Holding Co's current Enterprise Value is $132.89 Mil.
Scilex Holding Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scilex Holding Co (SCLX) has a EV-to-OCF of -7.78 as of Sep. 07, 2026. According to the industry distribution chart, Scilex Holding Co ranks #207 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 20.6%.
Is Scilex Holding Co's EV-to-OCF too high?
Scilex Holding Co's current EV-to-OCF is -7.78. Based on the distribution chart, Scilex Holding Co ranks #207 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Scilex Holding Co has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scilex Holding Co's EV-to-OCF compare to MIRA and NSRX?
According to the Drug Manufacturers industry distribution chart, Scilex Holding Co ranks #207 out of 1007 companies for EV-to-OCF. This places Scilex Holding Co in the top 21% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 10.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.44, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scilex Holding Co's current EV-to-OCF is -7.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scilex Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Scilex Holding Co (SCLX) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.33, compared to a current price of $5.38 — trading 15% below its estimated fair value. The current EV-to-OCF is -7.78. Scilex Holding Co's overall GF Score™ is 57/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Scilex Holding Co (SCLX), the current EV-to-OCF is -7.78 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Scilex Holding Co (SCLX) Overvalued in 2026?
Based on GuruFocus' analysis, Scilex Holding Co stock appears to be undervalued.
The current stock price of $5.38 is trading 15% below its estimated GF Value™ of $6.33.
GuruFocus considers Scilex Holding Co to be Modestly Undervalued.
Key valuation signals for SCLX:
EV-to-OCF: -7.78
GF Value™: $6.33 vs. price of $5.38 (15% below fair value)
No single metric tells the full story. See the SCLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
57GF Score
Get the complete analysis for SCLX
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCLX has been successfully added to your 
